Overview

A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs). In order to meet the aspiration of precision medicine, the in vivo murine models have been widely adopted. However, common constraints such as high cost, long duration of experiments, and low engraftment efficiency remained to be resolved. The chick embryo chorioallantoic membrane (CAM) is an alternative model to overcome some of these limitations. The chick CAM is shown to be a robust model for both the inoculation of cell lines and grafting of patient tumors for drug therapy evaluations and target genes/pathways analysis.

The start-up INOVOTION has developed a unique, highly sensitive and reproducible CAM assay to graft human cancer cells/tumors in the chicken egg environment. INOVOTION's technology was validated for over 55 human tumor cell lines, including carcinomas, gliomas and melanomas, as well as over 30 reference drugs currently on the market.

At INOVOTION, the graft of human cancer cells on the chicken CAM is currently conducted manually. To scale-up, the process was recently automated. The automation performance was assessed on cancer cells lines. The objective of this study is to demonstrate that the automation of the INOVOTION process enables tumors' proliferation using patient samples (from tumor samples or circulating tumor cells) as grafting material.

Eligibility

• Inclusion Criteria for all cohorts * :
  • Age > 18
  • Signed consent
  • Inclusion criteria for the "Prostate" cohort:
  • prostate adenocarcinoma histologically proven
  • metastatic situation
  • at least 2 metastatic sites
  • Evolutionary disease that requires a new treatment
  • Inclusion criteria for the "Breast" cohort:
  • HER2+ or RH+ breast adenocarcinoma histologically proven
  • metastatic situation
  • at least 2 metastatic sites
  • Evolutionary disease that requires a new treatment
  • Inclusion criteria for the "Lung" cohort:
  • Non Small Lung cancer histologically proven
  • metastatic situation
  • at least 2 metastatic sites
  • Evolutionary disease that requires a new treatment
  • Inclusion criteria for "Ovarian" cohort:
  • Ovarian cancer histologically proven
  • Presence of peritoneal carcinomatosis (stage IIIC or IV); with or without presence of peritoneal fluid
  • Inclusion criteria for "Colo-Rectal" cohort:
  • Colo-rectal cancer histologically proven
  • Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
  • Evolutionary disease that requires a new treatment
  • Inclusion criteria for "Gastric" cohort:
  • Gastric cancer histologically proven
  • Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
    • Exclusion Criteria for all cohorts * :
  • Weight <50kg
  • Parallel participation in a doubled blinded study
  • Brain or ganglionary metastasis only